Strategically speaking; institutional investors from the previous capital raising with risk free options would best be served by limiting the issuance of new shares in HyAct ACL (therefore higher ACL share price now) then pushing down the share price of HyAct ACL prior to conversion, to maximize the number of shares they are entitled too.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable